Samira Bensfia

425 total citations
9 papers, 67 citations indexed

About

Samira Bensfia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Samira Bensfia has authored 9 papers receiving a total of 67 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Samira Bensfia's work include Peptidase Inhibition and Analysis (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Treatment and Pharmacology (3 papers). Samira Bensfia is often cited by papers focused on Peptidase Inhibition and Analysis (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Treatment and Pharmacology (3 papers). Samira Bensfia collaborates with scholars based in Spain, France and United States. Samira Bensfia's co-authors include Sandeep Sehdev, Louise Provencher, Saeed Sadeghi, Guido Sauter, John Crown, Simon Hitier, Semiglazov Vf, Arlene Chan, Mansoor N. Saleh and Vincent Houé and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Samira Bensfia

8 papers receiving 67 citations

Peers

Samira Bensfia

ONCOL

PRM

HEMAT

José Rodrigo Espinosa Fernández United States

Swapnil Parmar United States

Geoffrey Fell United States

P. Dalivoust France

Puneeth Guruprasad United States

Laura Murillo Spain

Annette Kolodzie United States

Sonia Del Barco Berrón Spain

Michael P. Mullane United States

M. Untch Germany

José Rodrigo Espinosa Fernández United States

Samira Bensfia

44 ×0.8

ONCOL

26 ×0.9

10 ×0.7

PRM

17 ×1.4

5 ×0.5

HEMAT

Citations per year, relative to Samira Bensfia Samira Bensfia (= 1×) peers José Rodrigo Espinosa Fernández

Countries citing papers authored by Samira Bensfia

Since Specialization

Citations

This map shows the geographic impact of Samira Bensfia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samira Bensfia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samira Bensfia more than expected).

Fields of papers citing papers by Samira Bensfia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samira Bensfia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samira Bensfia. The network helps show where Samira Bensfia may publish in the future.

Co-authorship network of co-authors of Samira Bensfia

This figure shows the co-authorship network connecting the top 25 collaborators of Samira Bensfia. A scholar is included among the top collaborators of Samira Bensfia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samira Bensfia. Samira Bensfia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Brady, Keri J. S., et al.. (2025). A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews. BMC Cancer. 25(1). 88–88. 1 indexed citations

Espósito, F., Sun Young Rha, Marc Van den Eynde, et al.. (2022). 1261TiP CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA). Annals of Oncology. 33. S1124–S1124. 2 indexed citations

Paz-Ares, L., Rémi Veillon, Nicolás Isambert, et al.. (2022). 75TiP Open-label, phase II study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab + platinum-based chemotherapy +/− pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05). Annals of Oncology. 33. S65–S66. 2 indexed citations

Aguado, Carlos, Laia Vilà, Dolores Isla, et al.. (2021). 1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy. Annals of Oncology. 32. S1034–S1035. 2 indexed citations

Schjesvold, Fredrik, Paul G. Richardson, Michel Attal, et al.. (2019). Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood. 134(Supplement_1). 1893–1893. 8 indexed citations

Mackey, John R., Tadeusz Pieńkowski, John Crown, et al.. (2016). Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Annals of Oncology. 27(6). 1041–1047. 48 indexed citations

Akaza, Hideyuki, Giuseppe Procopio, Gaetano Facchini, et al.. (2014). Treatment Patterns in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Previously Treated with Docetaxel (Doc)-Based Chemotherapy (Ctx): Proxima. Annals of Oncology. 25. iv274–iv274.

Bavbek, Sevil, Zafar Malik, Giuseppe Di Lorenzo, et al.. (2012). A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology. 30(15_suppl). e15112–e15112. 3 indexed citations

Bavbek, Sevil, Zafar Malik, Inge M. van Oort, et al.. (2012). A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology. 30(5_suppl). 172–172. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact